Brooks Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BROOKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brooks Laboratories reported strong Q1 FY26 results, with standalone revenue from operations rising about 42% year-on-year to Rs. 2,551.19 lakhs (vs Rs. 1,793.29 lakhs in Q1 FY25). The company swung from a small loss of Rs. 21.23 lakhs last year to a standalone net profit of Rs. 265.06 lakhs, with EPS of Rs. 0.90. On a consolidated basis, net profit jumped to Rs. 958.48 lakhs (vs a loss of Rs. 241.34 lakhs), driven largely by a Rs. 693.42 lakhs share of profit from its joint venture Brooks Steriscience, which booked Rs. 2,083.56 lakhs in licensing income this quarter. The limited review was completed by a new auditor, D M K H & Co, replacing predecessor S G C O and Co. LLP, with a clean (unqualified) opinion.
Strong top-line growth and a clear swing to profit are positive for the stock, but consolidated earnings are heavily propped up by a one-time licensing windfall in the JV — investors should watch whether this is sustainable. The auditor change is worth noting but the clean review report limits immediate concerns.